Objective To review the efficacy and safety of low-dose versus standard-dose enzalutamide,
apalutamide or darolutamide treatment for metastatic prostate cancer. Methods and analysis …

Abstract Context Genitourinary cancers (GUCs) encompass malignancies affecting the
urinary and reproductive systems, including renal cell carcinoma (RCC), urothelial …

Background: Apalutamide is a new drug class, which is approved to treat prostate cancer
(PCa). The aim of our study was to assess the safety profiles of apalutamide in real-world …

Background CC-115, a dual mTORC1/2 and DNA-PK inhibitor, has promising antitumour
activity when combined with androgen receptor (AR) inhibition in pre-clinical models …

Background/objectives Based on the SPARTAN and TITAN studies, apalutamide is
approved for patients with nonmetastatic castration-resistant and metastatic castration …

Background Apalutamide-associated skin adverse events are more common in the
Japanese than in the global population. However, limited clinical data have hampered …

Androgen deprivation therapy (ADT) is the mainstay treatment for metastatic hormone-
sensitive prostate cancer (mHSPC). The addition of docetaxel or new hormone therapies …

Objective To evaluate the efficacy and safety of apalutamide prostate cancer compared to
the pivotal trials patients and to identify the first subsequent therapy in a real‐world setting …

La terapia de privación androgénica (TPA) es el pilar del tratamiento del cáncer de próstata
hormono-sensible metastásico (CPHSm). La adición de docetaxel o de nuevas terapias …

The landscape of available therapeutic options for treatment of genitourinary (GU) cancers is
expanding dramatically. Many of these treatments have distinct, sometimes severe, skin …